- Home
- ETV vs RARE Comparison
ETV vs RARE Comparison
Compare ETV & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
ETV
Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Current Price
Company Overview
Basic Information| Metric | ETV | RARE |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2005 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ETV | RARE |
|---|---|---|
| Price | $14.41 | $16.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 21 |
| Target Price | N/A | ★ $26.25 |
| AVG Volume (30 Days) | 155.5K | ★ 3.3M |
| Earning Date | 01-01-0001 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $673,000,000.00 |
| Revenue This Year | N/A | $12.96 |
| Revenue Next Year | N/A | $31.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.13 |
| 52 Week Low | $13.13 | $12.73 |
| 52 Week High | $15.49 | $39.89 |
Technical Indicators
Market Signals| Indicator | ETV | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 33.88 | 50.12 |
| Support Level | $14.29 | $14.11 |
| Resistance Level | $14.82 | $23.44 |
| Average True Range (ATR) | 0.15 | 0.75 |
| MACD | -0.02 | 0.32 |
| Stochastic Oscillator | 6.05 | 53.22 |
Price Performance
Historical ComparisonAbout ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.